MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia
Athalia R. Pyzer, David Avigan(Beth Israel Deaconess Medical Center), Poorvi Somaiya(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Rebecca Karp Leaf(California University of Pennsylvania), Leandra Cole(Beth Israel Deaconess Medical Center), Maxwell Coll, Hasan Rajabi(Harvard University), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Arie Apel(Tel Aviv University), Donald Küfe(Dana-Farber Cancer Institute), Malgorzata McMasters(Beth Israel Deaconess Medical Center), Myrna Nahas, Mary Paty Bryant(Beth Israel Deaconess Medical Center), Salvia Jain(Broad Institute), Lourdes Mendez(Beth Israel Deaconess Medical Center), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Jacqueline Fung(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Kristen Palmer(Beth Israel Deaconess Medical Center), Pier Paolo Pandolfi(University of Turin), Abigail Washington(Beth Israel Deaconess Medical Center), Ashujit Tagde(Dana-Farber Cancer Institute)
Cited by 193
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k